For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone. We analyzed the efficacy of long-term treatment with ≥10 cycles of docetaxel, and validated the risk group classification in predicting overall survival (OS) in Japanese patients with mCRPC. docetaxel and 8 mg dexamethasone, every 3 or 4 weeks, simultaneously with hormonal therapy and daily oral dexamethasone. They were divided into two groups, short-term (9 or fewer cycles) and long-term (10 or more cycles). Four risk factors including the presence of anemia, bone metastases, significant pain and visceral metastases were utilized for the risk ...
AbstractBackgroundWe retrospectively analyzed castration-resistant prostate cancer (CRPC) patients t...
We explored the association between Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and 1....
Micro-Abstract Individual patients' survival varies greatly in metastatic castration-resistant prost...
For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednison...
Purpose: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus ...
AbstractIntroductionDocetaxel-based chemotherapy has been demonstrated to improve survival in patien...
Aims of the study: There are no known predictive factors of response in men receiving chemotherapy f...
Introduction: Docetaxel-based chemotherapy has been demonstrated to improve survival in patients wit...
Importance The optimal total number of docetaxel cycles in patients with metastatic castration resis...
Castration-resistant prostate cancer (CRPC) patients have poor prognoses. Although many treatment op...
Purpose: With the emergence of various novel therapies including new generation taxane and androgen-...
Background: Docetaxel-based chemotherapy has been shown to be effective and well toler-ated by Weste...
Docetaxel has been shown to improve survival in patients with metastatic castrate-resistant prostate...
AbstractPurposeWith the emergence of various novel therapies including new generation taxane and and...
OBJECTIVE: To evaluate the benefit of docetaxel rechallenge in patients with metastatic castration-r...
AbstractBackgroundWe retrospectively analyzed castration-resistant prostate cancer (CRPC) patients t...
We explored the association between Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and 1....
Micro-Abstract Individual patients' survival varies greatly in metastatic castration-resistant prost...
For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednison...
Purpose: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus ...
AbstractIntroductionDocetaxel-based chemotherapy has been demonstrated to improve survival in patien...
Aims of the study: There are no known predictive factors of response in men receiving chemotherapy f...
Introduction: Docetaxel-based chemotherapy has been demonstrated to improve survival in patients wit...
Importance The optimal total number of docetaxel cycles in patients with metastatic castration resis...
Castration-resistant prostate cancer (CRPC) patients have poor prognoses. Although many treatment op...
Purpose: With the emergence of various novel therapies including new generation taxane and androgen-...
Background: Docetaxel-based chemotherapy has been shown to be effective and well toler-ated by Weste...
Docetaxel has been shown to improve survival in patients with metastatic castrate-resistant prostate...
AbstractPurposeWith the emergence of various novel therapies including new generation taxane and and...
OBJECTIVE: To evaluate the benefit of docetaxel rechallenge in patients with metastatic castration-r...
AbstractBackgroundWe retrospectively analyzed castration-resistant prostate cancer (CRPC) patients t...
We explored the association between Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and 1....
Micro-Abstract Individual patients' survival varies greatly in metastatic castration-resistant prost...